AMRICT Trial
Cross-source consensus on AMRICT Trial from 1 sources and 6 claims.
1 sources · 6 claims
Uses
Other
Other
Other
Highlighted claims
- The AMRICT trial is designed to compare gadoxetic acid abbreviated MRI with CT for detecting late recurrent HCC after curative treatment. — Multicentre prospective trial of abbreviated MRI using gadoxetic acid versus CT for detection of late recurrent HCC (AMRICT): study protocol
- AMRICT is a prospective multicentre intra-individual paired comparison study at three university-affiliated tertiary referral hospitals in South Korea. — Multicentre prospective trial of abbreviated MRI using gadoxetic acid versus CT for detection of late recurrent HCC (AMRICT): study protocol
- The required AMRICT enrollment is 455 participants after accounting for power, alpha, and dropout assumptions. — Multicentre prospective trial of abbreviated MRI using gadoxetic acid versus CT for detection of late recurrent HCC (AMRICT): study protocol
- Each AMRICT participant undergoes both imaging modalities to enable within-subject comparison and reduce inter-individual confounding. — Multicentre prospective trial of abbreviated MRI using gadoxetic acid versus CT for detection of late recurrent HCC (AMRICT): study protocol
- Enrollment for AMRICT opened on 12 December 2024 and is ongoing. — Multicentre prospective trial of abbreviated MRI using gadoxetic acid versus CT for detection of late recurrent HCC (AMRICT): study protocol
- A blinded interim sample size re-evaluation is planned after half of participants complete the first imaging round. — Multicentre prospective trial of abbreviated MRI using gadoxetic acid versus CT for detection of late recurrent HCC (AMRICT): study protocol